Sinovac Biotech ( (SVA) ) just unveiled an announcement.
On March 31, 2025, Sinovac Biotech Ltd. announced the appointment of Sven H. Borho, CFA, as a new board member and Chairman of the Audit Committee. Mr. Borho, a founder and Managing Partner of OrbiMed, brings over 30 years of healthcare investment experience to the company. This strategic appointment is expected to strengthen Sinovac’s governance and financial oversight, potentially enhancing its market position and stakeholder confidence.
More about Sinovac Biotech
Sinovac Biotech Ltd. is a China-based biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of vaccines for human infectious diseases. Their product portfolio includes vaccines for COVID-19, enterovirus 71, hepatitis A, varicella, influenza, poliomyelitis, and pneumococcal disease. Notably, their COVID-19 vaccine, CoronaVac, is approved in over 60 countries, and they are the sole supplier of the H5N1 pandemic influenza vaccine to the Chinese government.
Average Trading Volume: 8,227
Technical Sentiment Signal: Hold
Current Market Cap: $460.3M
For an in-depth examination of SVA stock, go to TipRanks’ Stock Analysis page.